Group news

Aspen increases revenue and progresses on medium-term priorities

Mar 5, 2020

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced unaudited interim financial results for the six months ended 31 December 2019. GROUP PERFORMANCE (CONTINUING OPERATIONS) Aspen increased revenue by 3% to R18,4 billion for the six months ended 31 December 2019. Commercial Pharma increased 2% to…

OPINION: Let’s pause for a moment to reflect on SA’s ARV success

Dec 4, 2019

By Stavros Nicolau, published in Independent Media’s Business Report JOHANNESBURG – Last week’s launch by Minister of Health Zweli Mkhize of a new ARV triple drug regimen in the Ugu district in KwaZulu-Natal and the commemoration of World Aids Day allows us as a country to reflect on how successfully we’ve managed what is arguably…

Aspen divests of its Japanese operations for up to R6.5 billion

Nov 11, 2019

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty and branded pharmaceutical company, is pleased to announced that its wholly owned subsidiary, Aspen Global Incorporated (“AGI”), has concluded an agreement to divest of Aspen’s Japanese operations and related intellectual property to Sandoz, a Novartis Division, for a cash consideration of…

Aspen generates strong second half cash flows, reducing borrowings

Sep 11, 2019

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced reviewed provisional Group financial results for the year ended 30 June 2019. Stephen Saad, Aspen Group Chief Executive said, “Despite the challenging environment, we have achieved most of our short-term goals, including the completion of the disposal…

Aspen hosts more than 120 Mandela Day projects in 40 countries

Jul 17, 2019

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, is again reaching out to less fortunate citizens through its Mandela Day projects being hosted on 6 continents. Stephen Saad, Aspen Group Chief Executive Stephen Saad, Aspen Group Chief Executive said, “This is the ninth year that we will…

Aspen opens anaesthetic building as part of €100 million investment at its French-based site

Jun 18, 2019

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has expanded its specialist sterile production site at Notre Dame de Bondeville in France to augment the Group’s global manufacturing facilities. Stephen Saad, Aspen Group Chief Executive said, “The new state-of-the-art facility for anaesthetics, together with the new high-speed…

Department of Health and PHEF celebrate investment in human resources

May 1, 2019

The South African National Department of Health (NDoH) and the Public Health Enhancement Fund (PHEF) celebrated their investment in human resources for health in honour of the late Prof Bongani Mayosi on 30 April 2019. The public and private healthcare sector leaders and professionals converged in honour of post-graduate and medical doctors from various healthcare…

Aspen approved for secondary listing on A2X

Mar 25, 2019

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has been approved for a secondary listing on A2X Markets with effect from 1 April 2019. Stephen Saad, Aspen Group Chief Executive said, “We continually strive to identify ways to increase value for our shareholders and the complementary A2X…

Aspen’s encouraging Emerging Market growth

Mar 8, 2019

Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has announced interim financial results for the six months ended 31 December 2018 in line with management’s expectations. Stephen Saad, Aspen Group Chief Executive said, “Revenue increases from Anaesthetics in China and Latin America of 6% and 22% respectively…

Aspen launches novel ARV Combination: Set to further improve treatment options

Nov 26, 2018

Johannesburg: Aspen Pharmacare, South Africa’s leading JSE-listed pharmaceutical company, is pleased to announce the launch of EmdoltenTM, a Dolutegravir-based triple combination anti-retroviral (ARV) treatment option. EmdoltenTM, a once a day triple combination tablet therapy in the form of Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate, is positioned to become a preferred first line ARV and will…

Aspen increases revenue and progresses on medium-term priorities

OPINION: Let’s pause for a moment to reflect on SA’s ARV success

Aspen divests of its Japanese operations for up to R6.5 billion

Aspen generates strong second half cash flows, reducing borrowings

Aspen hosts more than 120 Mandela Day projects in 40 countries

Aspen opens anaesthetic building as part of €100 million investment at its French-based site

Department of Health and PHEF celebrate investment in human resources

Aspen approved for secondary listing on A2X

Aspen’s encouraging Emerging Market growth

Aspen launches novel ARV Combination: Set to further improve treatment options

CONTACT DETAILS